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Abstract
Visual impairment due to inherited ophthalmic disorders is amongst the most common disabilities observed in populations
practicing consanguineous marriages. Here we investigated the molecular genetic basis of an unselected broad range of
ophthalmic disorders in 20 consanguineous families from Arab villages of Israel and the Palestinian Authority. Most patients
had little or very poor prior clinical workup and were recruited in a field study. Homozygosity mapping followed by
candidate gene sequencing applying conventional Sanger sequencing or targeted next generation sequencing was performed
in six families. In the remaining 14 families, one affected subject per family was chosen for whole exome sequencing. We
discovered likely disease-causing variants, all homozygous, in 19 of 20 independent families (95%) including a previously
reported novel disease gene for congenital nystagmus associated with foveal hypoplasia. Moreover, we found a family in
which disease-causing variants for two collagenopathies — Stickler and Knobloch syndrome — segregate within a large
sibship. Nine of the 19 distinct variants observed in this study were novel. Our study demonstrated a very high molecular
diagnostic yield for a highly diverse spectrum of rare ophthalmic disorders in Arab patients from Israel and the Palestinian
Authority, even with very limited prior clinical investigation. We conclude that ‘genetic testing first' may be an economic
way to direct clinical care and to support proper genetic counseling and risk assessment in these families.
Introduction
Hereditary ophthalmic diseases such as retinal dystrophies,
congenital cataract, and other developmental malformations
of the eye have considerable impact on social autonomy and
quality of life. In particular, infants with congenital visual
impairment show significant delays and difficulties regard-
ing their motor, cognitive, language, educational, social,
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and emotional development compared with sighted children
[1]. Molecular testing can help to provide a patient with
early diagnosis and potential treatment, and is further
required for accurate genetic counseling. Detection of
disease-causing variants in genetic diagnostic and research
testing has significantly improved with the introduction of
next-generation-sequencing technologies (NGS), especially
for rare diseases with a high level of clinical and genetic
heterogeneity [2].
Within the last two decades, major progress has been
made in our understanding of hereditary ophthalmic dis-
eases. Inherited retinal dystrophies (IRDs), a major cause
of childhood vision loss, are a heterogenic group of
blinding diseases with more than 225 genes known to be
mutated in the various clinical subtypes (https://sph.uth.
edu/retnet/). Besides the genetic complexity, phenotypic
overlaps and considerable variation in clinical expression
may hamper a distinct clinical diagnosis [3]. The different
disease entities result from variants in genes critical for
development and maintenance of retinal photoreceptors or
their supporting cells (for review, see ref. [4]). IRDs can
be stationary or progressive (for review, see ref. [5]), and
in the latter, vision worsens over time usually to the point
of legal blindness, which can occur in early infancy (i.e.
Leber congenital amaurosis) or later in life (i.e. retinitis
pigmentosa or cone–rod dystrophy).
Congenital eye malformations result from defects in
genes expressed during normal embryonic development,
and are a significant cause of blindness worldwide [6].
Such developmental ocular defects comprise congenital
cataract, congenital corneal anomalies (such as micro-
cornea and sclerocornea), coloboma, microphthalmia
(including nanophthalmos), anophthalmia and others,
invariably leading to poor or no visual function and cos-
metic disfigurement.
Most of these inherited ocular diseases are rare and a
proper diagnosis requires expert physicians or multi-
disciplinary consultations and high-end specialized
equipment for a differential diagnosis. However, high level
medical infrastructure is expensive and not available in
many parts of the world, leaving many patients without
appropriate diagnosis and thus precludes proper counsel-
ing or knowledge of potential treatment options. Dropping
prices for genome-wide genetic analysis such as exome
sequencing may offer an economic alternative as a primary
diagnostic measure in such scenarios.
Here we present the results of a genetic study on an
unselected highly diverse spectrum of rare ophthalmic
disorders in consanguineous Arab families from the
Palestinian Authority and mainland Israel. Our results
demonstrate the high sensitivity of current DNA-based
diagnostics for ophthalmic disorders in this population
even in families with poor prior clinical workup.
Materials and methods
Subjects
Study participants were recruited in Israel and the Palesti-
nian Authority. In most instances, the patients and family
members were recruited based on their self-reported
symptoms and visual impairments upon visits of a non-
ophthalmologist at the families’ home. Peripheral venous
blood was taken from all consenting participants and used
to isolate total genomic DNA applying standard procedures
according to the manufacturer’s protocol (FlexiGene DNA
Kit, QIAGEN, Hilden, Germany). DNA samples were sent
to the University of Tuebingen (Germany) for genetic
investigation. This study was performed according to the
tenets of the Declaration of Helsinki and written informed
consent was obtained from each study participant or from
the parents in case of minor study subjects.
SNP genotyping and homozygosity mapping
SNP genotyping was done applying Affymetrix 250K NspI
or CytoScan HD arrays (Affymetrix, Inc., Santa Clara, CA,
USA). SNP chip genotypes were called with the Affymetrix
Genotyping Console (GTC) Software v. 2.1 and used to
determine homozygous regions by applying the online
version of the HomozygosityMapper Software [7]. The
threshold was set to a minimum of 2Mb in length.
Exome sequencing
One affected patient per family underwent whole exome
sequencing (WES). Exonic regions were enriched using the
Agilent’s SureSelect XT Human All Exon v5 system (and
in one case by using the SeqCap EZ Human Exome Library
v2.0) according to the manufacturer's protocol (Illumina,
San Diego, CA, USA). Sequencing was performed on
Illumina HiSeq 2500 or NextSeq 500 instruments, and in
one case on an Illumina Genome Analyzer IIx (GAIIx)
instrument, in paired-end mode. WES was performed in 14
families (AQ10, AQ20, AQ21, AQ23, AQ24, AQ33,
AQ34, AQ46, AQ48, AQ52, AQ53, AQ55, TR16, and
MA08). For the (distantly) related families AQ33 and
AQ34, WES was performed on one affected patient per
family. In two families (AQ09 and TR21), variant detection
was done by targeted NGS of >4800 genes applying the
Illumina TruSight One Sequencing Panel (“clinical exome”)
on Illumina MiSeq and HiSeq instruments. Raw NGS data
were processed through an in-house pipeline (megSAP).
Alignment was performed with BWA-MEM (https://arxiv.
org/abs/1303.3997), freebayes (https://arxiv.org/abs/1207.
3907) was used for variant calling, and SnpEff [8] was used
for variant annotation. Variants were filtered for changes
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that are rare (minor allele frequency <1% due to The
Genome Aggregation Database (gnomAD)), in homo-
zygous state and in genes known/suggested to be associated
with human diseases (“TruSight One Sequencing Panel
filter”; 4813 genes).
Variant interpretation, Sanger sequencing, and
segregation analysis
Variants identified by NGS were validated by PCR and
subsequent Sanger sequencing using BigDye Terminator v.
1.1 chemistry and separation of sequencing products on a
3130xl Genetic Analyzer (Applied Biosystems, Weiterstadt,
Germany). Primer sequences are listed in Table S1. Segre-
gation analysis was done by Sanger sequencing with samples
from all available family members. Minor allele frequency
(MAF) data were obtained from The Genome Aggregation
Database (gnomAD) (http://gnomad.broadinstitute.org/;
accessed November 10, 2017). Variants were evaluated by the
following in silico tools: MutationTaster (https://www.muta
tiontaster.org/) [9], PolyPhen-2 (https://genetics.bwh.harvard.
edu/pph2/) [10], and SIFT (https://sift.jcvi.org/) [11], and
classified in accordance with the standards and guidelines
provided by the American College of Medical Genetics and
Genomics (ACMG) and the Association for Molecular
Pathology (AMP) [12] with the help of the Genetic Variant
Interpretation Tool https://www.medschool.umaryland.edu/
genetic_variant_interpretation_tool2.html/). Variants were
submitted to ClinVar.
Results
The inclusion criteria for subjects and families were defined
as follows: (1) bilateral ophthalmic disease or a disorder with
predominant visual symptomology, (2) at least two affected
subjects per family, and (3) likely autosomal recessive
inheritance with parental consanguinity. The study finally
comprised 20 independent Arab families from Israel and the
Palestinian Authority. In two instances we merged inde-
pendently recruited families (AQ11 and AQ12 as well as
AQ33 and AQ34), because we could establish familial
relationship and affected patients presented with very similar
conditions or symptoms. All families met the inclusion cri-
teria with the exception of AQ13. In this family, distantly
related to family AQ11/12, there was only a single affected
individual suffering from a complex phenotype with ocular
and neurodevelopmental symptoms. Only few families had
prior undergone a thorough clinical work up. In fact, the
majority of families were recruited through personal contacts
within their communities by visits at their home places in
order to inform them about the study, to interview the
patients and family members about their visual and other
health complaints and to collect blood samples. Therefore,
mostly very limited knowledge on the condition (i.e. 'night
blindness and gradual vision loss' or 'decreased vision and
sensitivity to light') was available prior to the genetic
investigation. Information on the origin, clinical diagnosis,
and genetic analysis are provided in Table 1 and all pedi-
grees and genotypes are shown in Fig. 1.
Applying homozygosity mapping and subsequent can-
didate gene analysis or — during the later stage of this
project — WES of a single affected patient per family, we
identified the most likely disease-causing gene variants in
19 of the 20 (95%) independent families (Table 2). One
family (AQ13) remained genetically unsolved.
Most likely disease-causing variants were observed in 15
different already known disease-associated genes (Table 2).
This includes several ultrarare disease genes such as PXDN
in ANTERIOR SEGMENT DYSGENESIS 7 (ASGD7;
OMIM 269400), VSX2 in MICROPHTHAMLIA (OMIM
610093), or SNX10 in autosomal recessive OSTEOPE-
TROSIS (OMIM 615085) for which very few affected
families have been reported hitherto. Moreover, in family
TR16 presenting with foveal hypoplasia and infantile nys-
tagmus, we identified a nonsense variant in a novel disease
candidate gene (AHR) as reported in detail elsewhere [13].
Of 19 different disease-associated variants (one of which
representing a complex allele) identified in the present
study, 10 were novel at the time of identification (Tables 1
and 2). However, the variant (c.2230C > T;p.(Arg744Ter))
introducing a premature stop codon in CRB1 was mean-
while reported [14]. Disease-associated variants comprised
seven different missense changes, five different variants
introducing a premature stop codon, five different indel
variants (small insertions and/or deletions; four of them
causing a frameshift), and one large deletion encompassing
five consecutive exons of the SPATA7 gene as well as
upstream sequences. The Stargardt disease patients of one
family (TR21) were shown to carry a complex ABCA4
allele (c.[5512C > G;c.5882G > A]). All disease-associated
variants were present in homozygous state in affecteds.
Surprisingly, we found that deleterious variants in two
collagen genes, COL9A2 and COL18A1, which are associated
with Stickler and Knobloch syndrome, respectively, are seg-
regating in family AQ48. COL9A2-linked Stickler syndrome
and COL18A1-linked Knobloch syndrome are two ultrarare
disorders with overlapping ophthalmic phenotype which—to
the best of our knowledge—have never been described
together in a single patient in the scientific literature before.
Discussion
In 19 of 20 consanguineous Arab families from Israel and
the Palestinian Authority with diverse ophthalmic
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conditions and mostly no or only rudimentary clinical data,
we identified disease-causing variants in 16 different genes,
including a novel candidate gene for foveal hypoplasia and
infantile nystagmus. The prevalence of hereditary recessive
diseases in Arab societies is high, mainly because of a long
tradition of consanguinity due to socio-cultural factors [15].
Consanguineous marriages in the Israeli Arab society were
shown to account for up to 40% of all marriages, and most
frequently occurred among first cousins [16, 17]. Therefore,
complex relationships within individual families and
affected family members in multiple generations are often
observed. Although consanguinity and the application of
homozygosity mapping, or filtering for homozygous var-
iants in exome sequencing data, likely facilitated the iden-
tification of the disease-causing variants, the high diagnostic
yield (95%) was remarkable given the heterogeneity of
conditions and the mostly poor or absent prior clinical
examination. Recruitment of the families was carried out
over a period of 6 years, mostly by visits of a non-
ophthalmologist at the families’ home (field study), and the
patients and family members were enrolled according to
their self-reported visual problems. Therefore we argue that
a concept of 'reverse diagnostics' by WES-based genetic
testing as a first tier approach can be highly efficient, and
further represent a model for countries or people with lim-
ited access to specialized ophthalmic clinical services.
Genotyping of available family members by PCR and
subsequent Sanger sequencing confirmed concordant seg-
regation in all but three families (AQ06, AQ10, and AQ20;
Fig. 1). False disease status information for some family
members may be the most likely explanation, as well as
accidental mislabeling or mix-up of samples during the field
study. Other, less likely possibilities includes reduced
penetrance or non-causality of the identified variants, either
in the entire family or in individual subjects.
Five of the 12 distinct disease-associated variants in nine
different genes associated with retinal dystrophies (isolated
and syndromic) were novel. To of them — a nonsense
variant in FAM161A in family AQ08 and a large deletion in
SPATA7 in family TR11 — have already been described in
detail elsewhere [18, 19].
In family TR21, three siblings had clinically been diag-
nosed with Stargardt disease, which was genetically con-
firmed by the identification of a homozygous ABCA4
variant. The ABCA4 complex allele (c.[5512C > G;5882G >
A]) seen in this family has previously been observed in two
siblings of a consanguineous Jordanian family, reported to
have a severe, early-onset phenotype of Stargardt disease
with severe macular atrophy and additional peripheral bone
spicule-like pigmentary deposits as seen in retinitis pig-
mentosa [20].
Retinal dystrophy in four families (AQ33/AQ34, AQ24,
AQ10, and AQ55) was CRB1-related. This is in line with a
study by Beryozkin et al., showing that CRB1 variants are a
relatively frequent cause of autosomal recessive early-onset
retinal degeneration in the Israeli and Palestinian popula-
tions [21]. Furthermore, the only recurrent disease-
associated variant in this study, CRB1: c.3307G > A; p.
(Gly1103Arg), observed in two unrelated families (AQ10
and AQ55), was demonstrated to be a true founder variant
in this population [21]. Disease-associated variants in CRB1
imply that the affected subjects in our families most likely
suffer from severe retinitis pigmentosa (RP12; ref. [22]) or
Leber congenital amaurosis [23], which is well compatible
with the symptomology described by the families. How-
ever, a definite diagnosis would require a detailed clinical
workup by an ophthalmologist in these cases.
Two families (AQ11/12 and AQ23) were shown to carry
known disease-causing variants in CNGA3, a gene asso-
ciated with achromatopsia or cone dystrophy [24]. Notably,
clinical trials to evaluate safety and efficacy of gene sup-
plementation therapy for CNGA3-linked achromatopsia are
currently underway including one multi-site trial,
NCT02935517, with a study site in Israel. This further
emphasizes the value of this study and testing strategy to
inform patients about clinical trials (usually at no costs for
the patient) and identify patients with rare conditions as
potential participants.
Family AQ11/12 has a further family branch (AQ13)
with a single affected individual (AQ13-05). This subject
had different symptoms (cerebellar atrophy with hearing
loss and decreased vision) compared to his affected cousins
in family branches AQ11 and AQ12, and did not carry the
CNGA3 variant. AQ13-05 remained the only unsolved
patient of this study although a separate WES analysis
was done.
A novel nonsense variant in GPR98 (also designated as
ADGRV1) was identified in a family with four children
suffering from both visual and hearing impairment (AQ09).
Variants in GPR98 account for a small but significant
proportion of subjects suffering from Usher syndrome type
2 (6.4%). Most of these GPR98 variants, as in our case,
result in a truncated protein product [25]. Of note, three of
four affected siblings in AQ09 were shown to be hetero-
zygous carriers of an additional complex USH2A allele (c.
[3959C > T;12052G > A]), which was inherited from the
mother). Both missense USH2A variants have already been
reported in Arab-Muslim families in the Jerusalem region
[26].
In family AQ20 with multiple affected patients reporting
a defect of vision and night blindness, a novel frameshift
variant (c.79delA; p.(Thr27Profs*26)) was identified in
RLBP1 encoding the cellular retinaldehyde-binding protein
(CRALBP). Variants in this gene have been reported to
cause autosomal recessive retinitis pigmentosa [27] or
retinitis punctata albescens [28], a subtype of retinitis
A. K. Mayer et al.
pigmentosa characterized by night blindness, delayed dark
adaptation, and the aggregation of small yellow-white dots
in the posterior pole.
Another gene involved in the intraretinal regeneration of
11-cis-retinal, RDH5, was mutated in family AQ06. The
observed missense variant (c.382G > A; p.(Asp128Asn))
has been reported in several prior studies [29–31] and was
shown to strongly reduce protein stability in COS-1 cells
[32]. Variants in RDH5 are associated with autosomal
recessive Fundus albipunctatus (FA), characterized by night
blindness and subretinal yellow-white spots [33]. In FA,
night blindness is usually stationary and visual acuity is
often normal which may compromise the ascertainment of
the clinical status in a field study and explain non-
concordant genotypes in this family.
Disease-associated variants in RPGRIP1 were first
described in 2001 in a study involving 57 unrelated patients
with Leber congenital amaurosis [34], and were also
reported to cause a clinically somewhat milder cone–rod
dystrophy [35]. In family AQ53, we observed a known
frameshift variant (c.1107delA; p.(Glu370Asnfs*5)) (ref.
[34]). The reported early disease onset in the affected family
members is in accordance with a Leber congenital
amaurosis-type of retinal dystrophy in family AQ53.
Affected family members of family AQ46 suffered from
osteopetrosis with complete vision loss and were shown to
carry a homozygous missense variant in the SNX10 gene.
Variants in SNX10 are reported to cause autosomal reces-
sive osteopetrosis type 8. Complete visual loss occurs
invariably in all untreated patients [36]. The disease is
frequently fatal during infancy unless treated by hemato-
poietic stem cell transplantation [37]. The SNX10 variant
(c.284G > A; p.(Arg95His)) observed in this study has
already been described in homozygous state in a female
patient from consanguineous parents with autism spectrum
disorder, developmental delay, and osteopetrosis [38].
Our study included two families with affected subjects
presenting with distinct ocular malformations, who were
found to carry homozygous missense variants in VSX2 and
PXDN, respectively. The VSX2 variant c.679C > T;
p.(Arg227Trp) has previously been reported in a large,
consanguineous Arab family with four affected patients
suffering from isolated microphthalmia/anophthalmia [39],
consistent with the findings (atrophic eye balls, complete
vision loss since birth) in family AQ52. Notably, VSX2-
associated ocular malformations are almost exclusively
reported from the Middle-East in families with parental
consanguinity [40]. The novel PXDN missense variant
(c.2459A > G; p.(Gln820Arg)) identified in family MA08
with congenital nanophthalmos and corneal opacification
affects a highly conserved amino acid as shown in Fig. 2. It
is also predicted to be disease-causing by MutationTaster,
SIFT, and PolyPhen-2, and further absent from the
gnomAD data set (Table 2). Prior reports describe similar
ocular anomalies (cataract-microcornea with corneal opa-
city, microphthalmia, and anterior segment dysgenesis) due
to variants in PXDN [41, 42].
Stickler syndrome type V and Knobloch syndrome type I
are caused by variants in the two different collagen genes
COL9A2 and COL18A1, respectively. Besides a single 5-
generation consanguineous family of Asian-Indian origin
segregating autosomal recessive Stickler syndrome that has
been identified to carry a biallelic 8-bp deletion in the
COL9A2 gene leading to a premature termination codon
(PTC) [43], only three more patients in two unrelated
families have been shown to harbor biallelic disease-
associated variants in this gene [44]. In the present study,
we now identified a novel missense variant c.1774G > A; p.
(Gly592Ser) affecting a highly conserved amino acid in the
collagen type IX alpha 2 chain (Fig. 2) in family AQ48,
likely representing the fourth case with Stickler syndrome
type V due to a biallelic COL9A2 variant. The variant was
predicted to be deleterious by all three in silico tools
(MutationTaster, SIFT, and PolyPhen-2) and observed with
a minor allele frequency of 8.802e−6 in gnomAD
(Table 2). The mother (AQ48-01-02) was found to be
homozygous for the COL9A2 variant and upon re-interview
reported to suffer from severe hearing impairment since
birth, requiring assistive devices. Note that neurosensory
hearing loss is a consistent feature in Stickler syndrome type
V. Family AQ48 additionally segregates a known 2-bp
deletion (c.3514_3515delCT; p.(Leu1172Valfs*72)) in
COL18A1 repeatedly reported in subjects with autosomal
recessive Knobloch syndrome [45–47]. The index patient in
AQ48 was homozygous for the COL9A2 as well as the 2-bp
deletion in COL18A1, which is unique, as—to the best of
our knowledge—Knobloch and Stickler syndrome have
never been observed together in a single individual before.
Accordingly, her phenotype was reported to be slightly
more severe compared to other affected family members
that were homozygous for either the COL9A2 or the
COL18A1 variant, or were triallelic.
Defects in GALK1 were shown to be responsible for
autosomal recessive congenital cataracts [48]. Galactoki-
nase (GALK1) is an enzyme involved in the first step of
galactose metabolism. Cataract formation in galactokinase-
deficient individuals is the result of osmotic phenomena
caused by the accumulation of galactitol, the reduction
product of galactose through an alternative pathway, in the
lens [49]. In family AQ21 with congenital cataract and a
novel 1-bp deletion (c.678delT; p.(Asn226Lysfs*38)) in
GALK1, extra-ocular symptoms (speech delay, hearing loss,
late walking, huge tongue, and hypothyroidism) have been
noted in the index patient. Severe speech delay was also
reported in two galactokinase-deficient brothers further
showing mental retardation and cataract [50]. In classic
Unraveling the genetic cause of hereditary ophthalmic disorders in Arab societies from Israel and the. . .
galactosemia (linked to defects in GALT) it has been shown
that speech, motor coordination, and strength disorders,
likely associated with diffuse cerebellar damage, co-occur
[51]. Hypothyroidism can be congenital and accompanied
by sensorineural hearing loss [52] and a large protruding
tongue [53]. This triad of symptoms is unlikely to be caused
by the 1-bp deletion in GALK1 given their absence in the
affected sister.
In family TR16, a novel disease gene for autosomal
recessive infantile nystagmus was identified as described in
detail elsewhere [13]. The three affected family members
were shown to be homozygous for a nonsense variant
(c.1861C > T; p.(Gln621Ter)) in the aryl hydrocarbon recep-
tor (AHR) gene encoding a ligand activated transcription
factor involved in various physiological and developmental
processes including neurogenesis. A knockout mouse model
showing similar disease expression supports our hypothesis
[54, 55]. This finding represents a novel disease entity char-
acterized by foveal hypoplasia and infantile nystagmus.
In this study, we demonstrated that the genetic causes of
highly heterogeneous ophthalmic disorders can be identified
with high efficacy in consanguineous Arab families, even
with no or sparse initial clinical data. Especially, exome
sequencing could serve as an economic diagnostic
approach, enabling efficient 'reverse diagnostics' and the
opportunity for tailored care, rehabilitation, and treatment.
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